Skip to content

West Pharmaceutical Services

NYSE: WST · USD

West Pharmaceutical Services financials

6 charts

Revenue

USD millions

$872.3M
West Pharmaceutical Services Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2010 Q2$281.8M; Change unavailable vs FY 2010 Q1
FY 2010 Q3$271.4M; −3.7% vs FY 2010 Q2
FY 2010 Q4$276.8M; +2.0% vs FY 2010 Q3
FY 2011 Q1$295.4M; +6.7% vs FY 2010 Q4
FY 2011 Q2$307.9M; +4.2% vs FY 2011 Q1
FY 2011 Q3$293.6M; −4.6% vs FY 2011 Q2
FY 2011 Q4$295.4M; +0.6% vs FY 2011 Q3
FY 2012 Q1$316.3M; +7.1% vs FY 2011 Q4
FY 2012 Q2$324.8M; +2.7% vs FY 2012 Q1
FY 2012 Q3$303.8M; −6.5% vs FY 2012 Q2
FY 2012 Q4$321.5M; +5.8% vs FY 2012 Q3
FY 2013 Q1$339.4M; +5.6% vs FY 2012 Q4
FY 2013 Q2$344.5M; +1.5% vs FY 2013 Q1
FY 2013 Q3$341.8M; −0.8% vs FY 2013 Q2
FY 2013 Q4$342.7M; +0.3% vs FY 2013 Q3
FY 2014 Q1$346.8M; +1.2% vs FY 2013 Q4
FY 2014 Q2$368.9M; +6.4% vs FY 2014 Q1
FY 2014 Q3$355.9M; −3.5% vs FY 2014 Q2
FY 2014 Q4$349.8M; −1.7% vs FY 2014 Q3
FY 2015 Q1$335.9M; −4.0% vs FY 2014 Q4
FY 2015 Q2$359.7M; +7.1% vs FY 2015 Q1
FY 2015 Q3$344.5M; −4.2% vs FY 2015 Q2
FY 2015 Q4$359.7M; +4.4% vs FY 2015 Q3
FY 2016 Q1$362.1M; +0.7% vs FY 2015 Q4
FY 2016 Q2$388M; +7.2% vs FY 2016 Q1
FY 2016 Q3$376.7M; −2.9% vs FY 2016 Q2
FY 2016 Q4$382.3M; +1.5% vs FY 2016 Q3
FY 2017 Q1$387.7M; +1.4% vs FY 2016 Q4
FY 2017 Q2$397.6M; +2.6% vs FY 2017 Q1
FY 2017 Q3$398.2M; +0.2% vs FY 2017 Q2
FY 2017 Q4$415.6M; +4.4% vs FY 2017 Q3
FY 2018 Q1$415.7M; 0.0% vs FY 2017 Q4
FY 2018 Q2$447.5M; +7.6% vs FY 2018 Q1
FY 2018 Q3$431.7M; −3.5% vs FY 2018 Q2
FY 2018 Q4$422.5M; −2.1% vs FY 2018 Q3
FY 2019 Q1$443.5M; +5.0% vs FY 2018 Q4
FY 2019 Q2$469.7M; +5.9% vs FY 2019 Q1
FY 2019 Q3$456.1M; −2.9% vs FY 2019 Q2
FY 2019 Q4$470.6M; +3.2% vs FY 2019 Q3
FY 2020 Q1$491.5M; +4.4% vs FY 2019 Q4
FY 2020 Q2$527.2M; +7.3% vs FY 2020 Q1
FY 2020 Q3$548M; +3.9% vs FY 2020 Q2
FY 2020 Q4$580.2M; +5.9% vs FY 2020 Q3
FY 2021 Q1$670.7M; +15.6% vs FY 2020 Q4
FY 2021 Q2$723.6M; +7.9% vs FY 2021 Q1
FY 2021 Q3$706.5M; −2.4% vs FY 2021 Q2
FY 2021 Q4$730.8M; +3.4% vs FY 2021 Q3
FY 2022 Q1$720M; −1.5% vs FY 2021 Q4
FY 2022 Q2$771.3M; +7.1% vs FY 2022 Q1
FY 2022 Q3$686.9M; −10.9% vs FY 2022 Q2
FY 2022 Q4$708.7M; +3.2% vs FY 2022 Q3
FY 2023 Q1$716.6M; +1.1% vs FY 2022 Q4
FY 2023 Q2$753.8M; +5.2% vs FY 2023 Q1
FY 2023 Q3$747.4M; −0.8% vs FY 2023 Q2
FY 2023 Q4$732M; −2.1% vs FY 2023 Q3
FY 2024 Q1$695.4M; −5.0% vs FY 2023 Q4
FY 2024 Q2$702.1M; +1.0% vs FY 2024 Q1
FY 2024 Q3$746.9M; +6.4% vs FY 2024 Q2
FY 2024 Q4$748.8M; +0.3% vs FY 2024 Q3
FY 2025 Q1$698M; −6.8% vs FY 2024 Q4
FY 2025 Q2$766.5M; +9.8% vs FY 2025 Q1
FY 2025 Q3$804.6M; +5.0% vs FY 2025 Q2
FY 2025 Q4$805M; 0.0% vs FY 2025 Q3
FY 2026 Q1$844.9M; +5.0% vs FY 2025 Q4
FY 2026 Q2$872.3M; +3.2% vs FY 2026 Q1
Jun 30, 2010 through Sep 25, 2026

Free cash flow

USD millions

$80.8M
West Pharmaceutical Services Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2010 Q2$16.7M; Change unavailable vs FY 2010 Q1
FY 2010 Q3$30.8M; +84.4% vs FY 2010 Q2
FY 2010 Q4$25.9M; −15.9% vs FY 2010 Q3
FY 2011 Q1$-9.9M; −138.2% vs FY 2010 Q4
FY 2011 Q2$21.3M; +315.2% vs FY 2011 Q1
FY 2011 Q3$15.5M; −27.2% vs FY 2011 Q2
FY 2011 Q4$8.4M; −45.8% vs FY 2011 Q3
FY 2012 Q1$-18.6M; −321.4% vs FY 2011 Q4
FY 2012 Q2$15.2M; +181.7% vs FY 2012 Q1
FY 2012 Q3$22.6M; +48.7% vs FY 2012 Q2
FY 2012 Q4$36.9M; +63.3% vs FY 2012 Q3
FY 2013 Q1$-42.8M; −216.0% vs FY 2012 Q4
FY 2013 Q2$57.4M; +234.1% vs FY 2013 Q1
FY 2013 Q3$24M; −58.2% vs FY 2013 Q2
FY 2013 Q4$30M; +25.0% vs FY 2013 Q3
FY 2014 Q1$-22.9M; −176.3% vs FY 2013 Q4
FY 2014 Q2$39.7M; +273.4% vs FY 2014 Q1
FY 2014 Q3$35.3M; −11.1% vs FY 2014 Q2
FY 2014 Q4$18.9M; −46.5% vs FY 2014 Q3
FY 2015 Q1$-32.3M; −270.9% vs FY 2014 Q4
FY 2015 Q2$50.8M; +257.3% vs FY 2015 Q1
FY 2015 Q3$39.1M; −23.0% vs FY 2015 Q2
FY 2015 Q4$23.2M; −40.7% vs FY 2015 Q3
FY 2016 Q1$-36M; −255.2% vs FY 2015 Q4
FY 2016 Q2$41.2M; +214.4% vs FY 2016 Q1
FY 2016 Q3$19.7M; −52.2% vs FY 2016 Q2
FY 2016 Q4$24.3M; +23.4% vs FY 2016 Q3
FY 2017 Q1$-16.8M; −169.1% vs FY 2016 Q4
FY 2017 Q2$55.8M; +432.1% vs FY 2017 Q1
FY 2017 Q3$41.5M; −25.6% vs FY 2017 Q2
FY 2017 Q4$52M; +25.3% vs FY 2017 Q3
FY 2018 Q1$17M; −67.3% vs FY 2017 Q4
FY 2018 Q2$61.8M; +263.5% vs FY 2018 Q1
FY 2018 Q3$61.9M; +0.2% vs FY 2018 Q2
FY 2018 Q4$43.2M; −30.2% vs FY 2018 Q3
FY 2019 Q1$18.8M; −56.5% vs FY 2018 Q4
FY 2019 Q2$76.8M; +308.5% vs FY 2019 Q1
FY 2019 Q3$76.4M; −0.5% vs FY 2019 Q2
FY 2019 Q4$68.8M; −9.9% vs FY 2019 Q3
FY 2020 Q1$25M; −63.7% vs FY 2019 Q4
FY 2020 Q2$111M; +344.0% vs FY 2020 Q1
FY 2020 Q3$71.1M; −35.9% vs FY 2020 Q2
FY 2020 Q4$91M; +28.0% vs FY 2020 Q3
FY 2021 Q1$34M; −62.6% vs FY 2020 Q4
FY 2021 Q2$87.5M; +157.4% vs FY 2021 Q1
FY 2021 Q3$124.8M; +42.6% vs FY 2021 Q2
FY 2021 Q4$84.3M; −32.5% vs FY 2021 Q3
FY 2022 Q1$85.4M; +1.3% vs FY 2021 Q4
FY 2022 Q2$107M; +25.3% vs FY 2022 Q1
FY 2022 Q3$111.1M; +3.8% vs FY 2022 Q2
FY 2022 Q4$135.9M; +22.3% vs FY 2022 Q3
FY 2023 Q1$56M; −58.8% vs FY 2022 Q4
FY 2023 Q2$93.8M; +67.5% vs FY 2023 Q1
FY 2023 Q3$134.3M; +43.2% vs FY 2023 Q2
FY 2023 Q4$130.4M; −2.9% vs FY 2023 Q3
FY 2024 Q1$27.6M; −78.8% vs FY 2023 Q4
FY 2024 Q2$64.8M; +134.8% vs FY 2024 Q1
FY 2024 Q3$98.8M; +52.5% vs FY 2024 Q2
FY 2024 Q4$85.2M; −13.8% vs FY 2024 Q3
FY 2025 Q1$58.1M; −31.8% vs FY 2024 Q4
FY 2025 Q2$101.9M; +75.4% vs FY 2025 Q1
FY 2025 Q3$133.9M; +31.4% vs FY 2025 Q2
FY 2025 Q4$175M; +30.7% vs FY 2025 Q3
FY 2026 Q1$47.2M; −73.0% vs FY 2025 Q4
FY 2026 Q2$80.8M; +71.2% vs FY 2026 Q1

Net margin

%

17.65%
West Pharmaceutical Services Net margin. Reported fiscal history.
Fiscal period%
FY 2010 Q27.7%
FY 2010 Q36.56%
FY 2010 Q4—
FY 2011 Q16.64%
FY 2011 Q26.53%
FY 2011 Q35.76%
FY 2011 Q4—
FY 2012 Q19.23%
FY 2012 Q24.8%
FY 2012 Q34.87%
FY 2012 Q46.56%
FY 2013 Q19.34%
FY 2013 Q28.77%
FY 2013 Q37.84%
FY 2013 Q46.89%
FY 2014 Q17.81%
FY 2014 Q210.19%
FY 2014 Q38.71%
FY 2014 Q48.98%
FY 2015 Q19.79%
FY 2015 Q27.73%
FY 2015 Q30.44%
FY 2015 Q49.29%
FY 2016 Q16.1%
FY 2016 Q211.52%
FY 2016 Q39.98%
FY 2016 Q410.23%
FY 2017 Q115.71%
FY 2017 Q29.76%
FY 2017 Q312.81%
FY 2017 Q40%
FY 2018 Q110.49%
FY 2018 Q212.54%
FY 2018 Q312.79%
FY 2018 Q412.31%
FY 2019 Q112.49%
FY 2019 Q214.07%
FY 2019 Q312.34%
FY 2019 Q413.58%
FY 2020 Q115.12%
FY 2020 Q217.3%
FY 2020 Q315.02%
FY 2020 Q416.96%
FY 2021 Q122.54%
FY 2021 Q225.88%
FY 2021 Q324.85%
FY 2021 Q420.21%
FY 2022 Q124.14%
FY 2022 Q224.44%
FY 2022 Q317.56%
FY 2022 Q414.53%
FY 2023 Q119.54%
FY 2023 Q220.58%
FY 2023 Q321.58%
FY 2023 Q418.72%
FY 2024 Q116.58%
FY 2024 Q215.85%
FY 2024 Q318.21%
FY 2024 Q417.37%
FY 2025 Q112.87%
FY 2025 Q217.2%
FY 2025 Q317.4%
FY 2025 Q416.41%
FY 2026 Q116.43%
FY 2026 Q217.65%

P/E

× · TTM · Daily

46.76×
West Pharmaceutical Services P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2013-02-28—2012-12-31
2013-03-28—2012-12-31
2013-04-30—2012-12-31
2013-05-31—2013-03-31
2013-06-28—2013-03-31
2013-07-31—2013-03-31
2013-08-30—2013-06-30
2013-09-30—2013-06-30
2013-10-31—2013-06-30
2013-11-29—2013-09-30
2013-12-31—2013-09-30
2014-01-31—2013-09-30
2014-02-28—2013-12-31
2014-03-31—2013-12-31
2014-04-30—2013-12-31
2014-05-30—2014-03-31
2014-06-30—2014-03-31
2014-07-31—2014-03-31
2014-08-29—2014-06-30
2014-09-30—2014-06-30
2014-10-31—2014-06-30
2014-11-28—2014-09-30
2014-12-31—2014-09-30
2015-01-30—2014-09-30
2015-02-27—2014-12-31
2015-03-31—2014-12-31
2015-04-30—2014-12-31
2015-05-29—2015-03-31
2015-06-30—2015-03-31
2015-07-31—2015-03-31
2015-08-31—2015-06-30
2015-09-30—2015-06-30
2015-10-30—2015-06-30
2015-11-30—2015-09-30
2015-12-31—2015-09-30
2016-01-29—2015-09-30
2016-02-29—2015-12-31
2016-03-31—2015-12-31
2016-04-29—2015-12-31
2016-05-31—2016-03-31
2016-06-30—2016-03-31
2016-07-29—2016-03-31
2016-08-31—2016-06-30
2016-09-30—2016-06-30
2016-10-31—2016-06-30
2016-11-30—2016-09-30
2016-12-30—2016-09-30
2017-01-31—2016-09-30
2017-02-28—2016-09-30
2017-03-31—2016-12-31
2017-04-28—2016-12-31
2017-05-31—2017-03-31
2017-06-30—2017-03-31
2017-07-31—2017-03-31
2017-08-31—2017-06-30
2017-09-29—2017-06-30
2017-10-31—2017-06-30
2017-11-30—2017-09-30
2017-12-29—2017-09-30
2018-01-31—2017-09-30
2018-02-28—2017-09-30
2018-03-29—2017-09-30
2018-04-30—2017-09-30
2018-05-31—2018-03-31
2018-06-29—2018-03-31
2018-07-31—2018-03-31
2018-08-31—2018-06-30
2018-09-28—2018-06-30
2018-10-31—2018-09-30
2018-11-30—2018-09-30
2018-12-31—2018-09-30
2019-01-31—2018-09-30
2019-02-28—2018-09-30
2019-03-29—2018-09-30
2019-04-30—2018-09-30
2019-05-31—2018-09-30
2019-06-28—2018-09-30
2019-07-31—2018-09-30
2019-08-30—2018-09-30
2019-09-30—2018-09-30
2019-10-31—2018-09-30
2019-11-29—2018-09-30
2019-12-31—2018-09-30
2020-01-31—2018-09-30
2020-02-28—2018-09-30
2020-03-31—2018-09-30
2020-04-30—2018-09-30
2020-05-29—2018-09-30
2020-06-30—2018-09-30
2020-07-31—2018-09-30
2020-08-31—2018-09-30
2020-09-30—2018-09-30
2020-10-30—2018-09-30
2020-11-30—2018-09-30
2020-12-31—2018-09-30
2021-01-29—2018-09-30
2021-02-2661.93×2020-12-31
2021-03-3162.18×2020-12-31
2021-04-3072.49×2020-12-31
2021-05-2876.68×2020-12-31
2021-06-3079.24×2020-12-31
2021-07-3090.86×2020-12-31
2021-08-3199.66×2020-12-31
2021-09-3093.68×2020-12-31
2021-10-2994.86×2020-12-31
2021-11-3097.68×2020-12-31
2021-12-31103.5×2020-12-31
2022-01-3186.77×2020-12-31
2022-02-2845.49×2021-12-31
2022-03-3148.27×2021-12-31
2022-04-2934.99×2022-03-31
2022-05-3134.47×2022-03-31
2022-06-3033.58×2022-03-31
2022-07-2937.98×2022-06-30
2022-08-3132.8×2022-06-30
2022-09-3027.21×2022-06-30
2022-10-3127.62×2022-09-30
2022-11-3028.17×2022-09-30
2022-12-3028.25×2022-09-30
2023-01-3131.88×2022-09-30
2023-02-2840.85×2022-12-31
2023-03-3144.65×2022-12-31
2023-04-2849.53×2023-03-31
2023-05-3145.88×2023-03-31
2023-06-3052.44×2023-03-31
2023-07-3153.5×2023-06-30
2023-08-3159.15×2023-06-30
2023-09-2954.54×2023-06-30
2023-10-3142.84×2023-09-30
2023-11-3047.22×2023-09-30
2023-12-2947.4×2023-09-30
2024-01-3150.21×2023-09-30
2024-02-2945.12×2023-12-31
2024-03-2849.82×2023-12-31
2024-04-3045.01×2023-12-31
2024-05-3141.72×2023-12-31
2024-06-2841.47×2023-12-31
2024-07-3138.55×2023-12-31
2024-08-3039.48×2023-12-31
2024-09-3037.79×2023-12-31
2024-10-3138.77×2023-12-31
2024-11-2941×2023-12-31
2024-12-3141.24×2023-12-31
2025-01-3143×2023-12-31
2025-02-2834.61×2024-12-31
2025-03-3133.35×2024-12-31
2025-04-3031.48×2024-12-31
2025-05-3031.41×2024-12-31
2025-06-3032.6×2024-12-31
2025-07-3135.64×2024-12-31
2025-08-2936.79×2024-12-31
2025-09-3039.08×2024-12-31
2025-10-3141.65×2025-09-30
2025-11-2840.94×2025-09-30
2025-12-3140.62×2025-09-30
2026-01-3034.13×2025-09-30
2026-02-2737.45×2025-12-31
2026-03-3136.91×2025-12-31
2026-04-3039.7×2026-03-31
2026-05-2943.07×2026-03-31
2026-06-3047.89×2026-03-31
2026-07-3143.03×2026-06-30
2026-08-3143.05×2026-06-30
2026-09-2546.76×2026-06-30
Mean 48.37×Median 42.18×11% above median

ROIC

% · Annual / TTM

20.04%
West Pharmaceutical Services ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q1—
FY 2011 Q27.68%
FY 2011 Q37.63%
FY 2011 Q49.16%
FY 2012 Q19.51%
FY 2012 Q29.83%
FY 2012 Q39.5%
FY 2012 Q49.99%
FY 2013 Q19.89%
FY 2013 Q210.73%
FY 2013 Q311.7%
FY 2013 Q411.64%
FY 2014 Q110.69%
FY 2014 Q211.51%
FY 2014 Q311.94%
FY 2014 Q412.56%
FY 2015 Q112.59%
FY 2015 Q211.69%
FY 2015 Q39.32%
FY 2015 Q49.54%
FY 2016 Q18.01%
FY 2016 Q29.28%
FY 2016 Q312.3%
FY 2016 Q412.82%
FY 2017 Q115.02%
FY 2017 Q214.5%
FY 2017 Q315.22%
FY 2017 Q412.22%
FY 2018 Q110.11%
FY 2018 Q211.47%
FY 2018 Q311.61%
FY 2018 Q415.94%
FY 2019 Q116.33%
FY 2019 Q217.37%
FY 2019 Q317.82%
FY 2019 Q417.88%
FY 2020 Q118.81%
FY 2020 Q220.32%
FY 2020 Q321.83%
FY 2020 Q423.11%
FY 2021 Q127.06%
FY 2021 Q231.92%
FY 2021 Q336.65%
FY 2021 Q438.83%
FY 2022 Q137.94%
FY 2022 Q236.59%
FY 2022 Q335.45%
FY 2022 Q431.9%
FY 2023 Q128.61%
FY 2023 Q226.13%
FY 2023 Q325.7%
FY 2023 Q426.34%
FY 2024 Q124.3%
FY 2024 Q221.76%
FY 2024 Q320.22%
FY 2024 Q420.08%
FY 2025 Q118.54%
FY 2025 Q218.61%
FY 2025 Q318.32%
FY 2025 Q418.71%
FY 2026 Q120.03%
FY 2026 Q220.04%

Capital allocation

% of tracked cash uses

$215.6M
West Pharmaceutical Services capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2010 Q273.04% · $14.9M0% · $0M0.49% · $0.1M26.47% · $5.4MUnavailable100% · $20.4M
FY 2010 Q369.08% · $17.2M9.64% · $2.4MUnavailable21.29% · $5.3MUnavailable100% · $24.9M
FY 2010 Q478.6% · $21.3M0% · $0M0.37% · $0.1M21.03% · $5.7MUnavailable100% · $27.1M
FY 2011 Q172.12% · $19.4M0% · $0M7.81% · $2.1M20.07% · $5.4MUnavailable100% · $26.9M
FY 2011 Q271.32% · $18.4M0% · $0M5.43% · $1.4M23.26% · $6MUnavailable100% · $25.8M
FY 2011 Q380.94% · $24.2M0% · $0M0% · $0M19.06% · $5.7M0% · $0M100% · $29.9M
FY 2011 Q484.56% · $33.4M0% · $0M0% · $0M15.44% · $6.1M0% · $0M100% · $39.5M
FY 2012 Q182.86% · $32.4MUnavailable1.53% · $0.6M15.6% · $6.1MUnavailable100% · $39.1M
FY 2012 Q282.77% · $37MUnavailable3.58% · $1.6M13.65% · $6.1MUnavailable100% · $44.7M
FY 2012 Q382.62% · $29MUnavailable0% · $0M17.38% · $6.1M0% · $0M100% · $35.1M
FY 2012 Q478.33% · $32.9MUnavailable5.95% · $2.5M15.71% · $6.6MUnavailable100% · $42M
FY 2013 Q190.47% · $61.7MUnavailableUnavailable9.53% · $6.5MUnavailable100% · $68.2M
FY 2013 Q277% · $22.1MUnavailableUnavailable23% · $6.6MUnavailable100% · $28.7M
FY 2013 Q381.62% · $29.3MUnavailableUnavailable18.38% · $6.6MUnavailable100% · $35.9M
FY 2013 Q484.53% · $38.8MUnavailableUnavailable15.47% · $7.1MUnavailable100% · $45.9M
FY 2014 Q181.7% · $31.7MUnavailableUnavailable18.3% · $7.1MUnavailable100% · $38.8M
FY 2014 Q277.78% · $24.5MUnavailableUnavailable22.22% · $7MUnavailable100% · $31.5M
FY 2014 Q380.11% · $28.6MUnavailableUnavailable19.89% · $7.1MUnavailable100% · $35.7M
FY 2014 Q477.43% · $27.1MUnavailableUnavailable22.57% · $7.9MUnavailable100% · $35M
FY 2015 Q179.37% · $30.4MUnavailable0% · $0M20.63% · $7.9MUnavailable100% · $38.3M
FY 2015 Q277.17% · $26.7MUnavailable0% · $0M22.83% · $7.9MUnavailable100% · $34.6M
FY 2015 Q378.99% · $29.7MUnavailable0% · $0M21.01% · $7.9MUnavailable100% · $37.6M
FY 2015 Q483.74% · $44.8MUnavailable0% · $0M16.26% · $8.7MUnavailable100% · $53.5M
FY 2016 Q168.66% · $39MUnavailable16.02% · $9.1M15.32% · $8.7MUnavailable100% · $56.8M
FY 2016 Q267.44% · $35MUnavailable15.61% · $8.1M16.96% · $8.8MUnavailable100% · $51.9M
FY 2016 Q372.69% · $48.7MUnavailable14.33% · $9.6M12.99% · $8.7MUnavailable100% · $67M
FY 2016 Q457.58% · $47.5MUnavailable30.79% · $25.4M11.64% · $9.6MUnavailable100% · $82.5M
FY 2017 Q150.74% · $37.5MUnavailable36.4% · $26.9M12.86% · $9.5MUnavailable100% · $73.9M
FY 2017 Q275.45% · $29.5MUnavailable0% · $0M24.55% · $9.6MUnavailable100% · $39.1M
FY 2017 Q378.13% · $34.3MUnavailable0% · $0M21.87% · $9.6MUnavailable100% · $43.9M
FY 2017 Q433.75% · $29.5MUnavailable54.35% · $47.5M11.9% · $10.4MUnavailable100% · $87.4M
FY 2018 Q132.44% · $28MUnavailable55.5% · $47.9M12.05% · $10.4MUnavailable100% · $86.3M
FY 2018 Q237.83% · $20.2MUnavailable42.88% · $22.9M19.29% · $10.3MUnavailable100% · $53.4M
FY 2018 Q372.01% · $26.5MUnavailable0% · $0M27.99% · $10.3MUnavailable100% · $36.8M
FY 2018 Q472.99% · $30MUnavailable0% · $0M27.01% · $11.1MUnavailable100% · $41.1M
FY 2019 Q123.41% · $28.8MUnavailable67.56% · $83.1M9.02% · $11.1M0% · $0M100% · $123M
FY 2019 Q271.83% · $28.3MUnavailable0% · $0M28.17% · $11.1MUnavailable100% · $39.4M
FY 2019 Q374.07% · $31.7MUnavailable0% · $0M25.93% · $11.1MUnavailable100% · $42.8M
FY 2019 Q476.11% · $37.6MUnavailable0% · $0M23.89% · $11.8MUnavailable100% · $49.4M
FY 2020 Q120.06% · $32.1MUnavailable72.19% · $115.5M7.38% · $11.8M0.38% · $0.6M100% · $160M
FY 2020 Q275.87% · $37.1MUnavailable0% · $0M24.13% · $11.8MUnavailable100% · $48.9M
FY 2020 Q379.97% · $47.5MUnavailable0% · $0M20.03% · $11.9MUnavailable100% · $59.4M
FY 2020 Q482.08% · $57.7MUnavailable0% · $0M17.92% · $12.6MUnavailable100% · $70.3M
FY 2021 Q126.76% · $54.7MUnavailable67.07% · $137.1M6.16% · $12.6MUnavailable100% · $204.4M
FY 2021 Q281.87% · $56.9MUnavailable0% · $0M18.13% · $12.6MUnavailable100% · $69.5M
FY 2021 Q383.83% · $65.3MUnavailable0% · $0M16.17% · $12.6MUnavailable100% · $77.9M
FY 2021 Q485.19% · $76.5MUnavailable0% · $0M14.81% · $13.3MUnavailable100% · $89.8M
FY 2022 Q129.08% · $65.8MUnavailable65% · $147.1M5.92% · $13.4MUnavailable100% · $226.3M
FY 2022 Q261.32% · $66.1MUnavailable26.53% · $28.6M12.15% · $13.1MUnavailable100% · $107.8M
FY 2022 Q358.68% · $57.8MUnavailable27.61% · $27.2M13.71% · $13.5MUnavailable100% · $98.5M
FY 2022 Q487.06% · $94.9MUnavailableUnavailable12.94% · $14.1MUnavailable100% · $109M
FY 2023 Q152.53% · $82.1MUnavailable38.45% · $60.1M9.02% · $14.1MUnavailable100% · $156.3M
FY 2023 Q228.68% · $75.4MUnavailable65.96% · $173.4M5.36% · $14.1MUnavailable100% · $262.9M
FY 2023 Q369.62% · $95.8MUnavailable20.2% · $27.8M10.17% · $14MUnavailable100% · $137.6M
FY 2023 Q436.17% · $108.7MUnavailable58.9% · $177M4.93% · $14.8MUnavailable100% · $300.5M
FY 2024 Q124.3% · $90.6MUnavailable71.6% · $267M3.94% · $14.7M0.16% · $0.6M100% · $372.9M
FY 2024 Q229.7% · $100.2MUnavailable55.45% · $187.1M4.33% · $14.6M10.52% · $35.5M100% · $337.4M
FY 2024 Q328.92% · $81.3MUnavailable18.64% · $52.4M5.16% · $14.5M47.28% · $132.9M100% · $281.1M
FY 2024 Q460.08% · $104.9MUnavailable31.16% · $54.4M8.76% · $15.3M0% · $0M100% · $174.6M
FY 2025 Q132.41% · $71.3MUnavailable60.68% · $133.5M6.91% · $15.2M0% · $0M100% · $220M
FY 2025 Q282.82% · $75.2MUnavailable0.55% · $0.5M16.63% · $15.1M0% · $0M100% · $90.8M
FY 2025 Q380.74% · $63.3MUnavailable0% · $0M19.26% · $15.1M0% · $0M100% · $78.4M
FY 2025 Q482.81% · $76.1MUnavailable0% · $0M17.19% · $15.8M0% · $0M100% · $91.9M
FY 2026 Q111.99% · $42.7MUnavailable83.57% · $297.6M4.44% · $15.8MUnavailable100% · $356.1M
FY 2026 Q220.04% · $43.2MUnavailable72.68% · $156.7M7.28% · $15.7MUnavailable100% · $215.6M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for West Pharmaceutical Services.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources